https://www.medpagetoday.com/cardiology/diabetes/85048

Also known as Trulicity, has been given a wide approval for MACE prevention for diabetic patients.  What impact does this have for Apabetalone's addressable market?

Also, does this mean that Eli Lilly is no longer a real buyer of RVX?

Thanks

Iconoclast